EU Paediatric Regulation Report ‘Positive,’ But More Investigation Needed, Legal Expert Claims
Executive Summary
The new EU report on how the Paediatric Regulation is working after 10 years is a “positive step forward,” says a legal expert, who also wants the commission to use its postponement of any future legislative changes as an opportunity to further examine – and discuss with all stakeholders – how to improve the procedure concerning pediatric investigation plans. The expert also raises concerns about some of the figures cited in the report.
You may also be interested in...
EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2nd Biosimilar Herceptin
A new ATMP, two generics and a biosimilar got the thumbs up this week from the European Medicines Agency’s drug evaluation committee, the CHMP. The committee also recommended one product for conditional authorization and another for a pediatric use authorization, But it turned down a potential multiple myeloma therapy derived from sea squirts.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.